Skip to main content
TipRanks
Go Ultimate75% OFF

Avicanna (AVCN) AI Stock Analysis

20 Followers
TSE:AVCN

Avicanna

(TSX:AVCN)

Select Model
Rating:42Neutral
Price Target:CAD 0.09▼(-4.44% Downside)
Action:reiterated
Date:11/14/26

The score is primarily held down by weak profitability, persistent negative cash flow, and poor technical momentum. Positive adjusted EBITDA, improving margins year over year, low leverage, and product and international initiatives provide some offset, but the negative P/E and ongoing funding needs keep the overall rating near the bottom of the range.

Positive Factors
Improving Operating EconomicsThe first positive adjusted EBITDA quarter, combined with substantial expense reductions, shows operating leverage is beginning to emerge. If management sustains recurring cost discipline and margin improvements, the business could move closer to durable profitability and reduce dependence on external funding.
Negative Factors
Persistent Losses and Cash BurnContinued losses and negative operating and free cash flow indicate that the business has not yet converted its product platform into self-sustaining cash generation. Until profitability improves, ongoing cash burn can constrain investment capacity and increase reliance on financing.

Avicanna (AVCN) vs. iShares MSCI Canada ETF (EWC)

-80%-60%-40%-20%0%20%40%TSE:AVCN-64.00%EWC+17.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 8.57M
Dividend Yield
―
Average Volume (3M)
180.58K
Price to Earnings (P/E)
-4.1
Beta (1Y)
1.43
Revenue Growth
-3.32%
EPS Growth
-34.15%
Country
Canada
Employees
112
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Avicanna Business Overview & Revenue Model

Company Description

Avicanna Inc., a biopharmaceutical firm headquartered in Toronto, Canada, and founded in 2016, is actively engaged in the research, development, and commercialization of scientifically validated products for both global medical and consumer health ma...

Avicanna Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:5.88%|Next Earnings Date:May 25, 2020
Earnings Call SentimentPositive

The call was broadly positive. Management highlighted the first positive adjusted EBITDA quarter, improving operating results, stronger gross margins year-over-year, reduced expenses, improved working capital, growth in proprietary and international revenue, the launch and expansion of the QUIX portfolio, and progress in clinical, pharmaceutical, and international initiatives. These positives were tempered by a 10% year-over-year revenue decline, lower gross profit, sequential gross-margin compression, negative operating cash flow, the impact of Veterans Affairs Canada reimbursement changes, licensing revenue variability, debt obligations, and the company's low market valuation.

Positive Updates

Ten-Year Milestone and Expanded Business Platform
Avicanna will reach its 10-year anniversary next week. The company has evolved into an international biopharmaceutical company with 68 commercial SKUs, 1 pharmaceutical product, several clinical programs, and established international commercial operations.

Negative Updates

Year-over-Year Revenue Decline
Q3 revenue declined 10% year-over-year to $5.7 million, primarily due to Veterans Affairs Canada reimbursement changes that reduced reimbursement for veteran patients by 29% effective April 1, along with lower licensing revenue.

Company Guidance

For Q4, management expects to continue the cost discipline, launch further QUIX SKUs across the Canadian market, improve the MyMedi percentage of sales, and generate “some early signals of international revenue growth”; it expects the majority of recent G&A savings to be recurring into Q4 and going into next year, expects to file an SR&ED claim every year going forward, and expects the Avicanna share of MyMedi sales to trend towards “40% to even 50% of the sales.” Management expects further SKU launches, margin efficiencies, and signals of growth going into Q4, early signals from SMGH this year and next year, significant pharmaceutical milestones going into 2027, and U.S. rescheduling “towards the end of this year or early next year.”

Avicanna Financial Statement Overview

Summary

Financial performance is very weak: revenue declined, the company remains unprofitable, and operating and free cash flow are negative. Low leverage and improved equity provide some support, but the underlying financial score is constrained by persistent losses and cash consumption.

Income Statement

25Negative

Balance Sheet

55Neutral

Cash Flow

20Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Dec 2024Mar 2024Dec 2022Mar 2022
Income Statement
Total Revenue24.65M25.48M25.46M16.79M4.05M3.27M
Gross Profit13.09M12.84M12.90M6.66M1.11M2.83M
EBITDA-1.57M-1.97M-2.43M-7.36M-12.18M-15.13M
Net Income-2.69M-2.84M-3.62M-8.74M-14.73M-16.77M
Balance Sheet
Total Assets23.36M21.24M20.12M21.97M17.62M22.30M
Cash, Cash Equivalents and Short-Term Investments151.23K280.63K448.03K477.20K1.19M31.00K
Total Debt258.57K0109.23K1.80M3.21M1.66M
Total Liabilities8.73M9.86M10.38M14.00M14.16M15.39M
Stockholders Equity5.16M2.84M2.31M-112.50K-383.56K1.15M
Cash Flow
Free Cash Flow-3.22M-1.44M-2.95M-1.96M-7.50M-12.45M
Operating Cash Flow-3.05M-1.18M-2.55M-1.40M-7.44M-11.66M
Investing Cash Flow-178.83K-255.84K-402.57K-3.05M810.24K760.83K
Financing Cash Flow2.82M963.17K3.41M3.55M9.90M10.06M

Avicanna Technical Analysis

Technical Analysis SentimentNegative
Last Price0.09

Price Trends

50DMA0.11Negative
100DMA0.12Negative
200DMA0.13Negative

Market Momentum

MACD-0.00Positive
RSI41.52Neutral
STOCH33.33Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AVCN, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.11, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 41.52 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AVCN.

Avicanna Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:AVCN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:LABSTSE:LABS57NeutralCAD 27.77M-9.23-7.66%―-9.31%66.84%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:INNOTSE:INNO45NeutralCAD 7.42M-5.56-19.37%―-19.20%42.54%
TSE:AVCNTSE:AVCN42NeutralCAD 12.09M-4.09-65.40%―-3.32%-34.15%
TSE:CWEBTSE:CWEB42NeutralCAD 65.11M-0.87-139.31%―-9.90%-35.35%
TSE:PCLOTSE:PCLO39UnderperformCAD 9.34M-2.6728.59%―0.90%57.73%
TSE:CRDLTSE:CRDL38UnderperformCAD 167.72M-4.19-159.80%――19.57%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%800%TSE:AVCNTSE:CWEBTSE:LABSTSE:PCLOTSE:CRDLTSE:INNODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:AVCN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:AVCNAvicanna Inc0.09-0.17-65.38%
TSE:CWEBCharlotte's Web Holdings (OTC)0.250.1287.97%
TSE:LABSMedipharm Labs (Otc)0.070.000.00%
TSE:PCLOPharmacielo0.040.000.00%
TSE:CRDLCardiol Therapeutics Inc.1.39-0.02-1.42%
TSE:INNOInnocan Pharma Corporation1.65-13.74-89.28%

Avicanna Corporate Events

Business Operations and StrategyDelistings and Listing Changes

Avicanna Moves U.S. Listing to OTCQB to Bolster Investor Access

Positive
Oct 16, 2026

Avicanna Inc., a cannabinoid-focused biopharmaceutical company listed in Canada and Europe, is expanding its presence in the U.S. capital markets through a transition of its U.S. listing to the OTCQB tier effective October 16, 2026. The move to OTCQB...

Business Operations and StrategyProduct-Related Announcements

Avicanna Expands MyMedi.ca Platform with Integrated Medical Cannabis Program in Canadian Healthcare

Positive
Sep 9, 2026

Avicanna has launched the MyMedi.ca Integrated Healthcare Program in Canada to embed healthcare provider-guided medical cannabis care within hospitals, specialty clinics, insurers and multidisciplinary healthcare networks. The initiative extends the...

Business Operations and StrategyPrivate Placements and Financing

Avicanna Secures Strategic Private Placement Led by Pharma Investor Michael Porter

Positive
Aug 19, 2026

Avicanna Inc., a biopharmaceutical company focused on plant-derived cannabinoid-based products for global medical and pharmaceutical markets, has built a diversified platform spanning branded medical cannabis, a patient-centric care portal, clinical-...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026